SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

EVOLVE II Clinical Trial 12 Month Primary Outcomes

SYNERGY Stent demonstrated exceptional outcomes in the EVOLVE II Clinical Trial, the first successful U.S. Pivotal Trial of a bioabsorbable polymer technology.

Most complex patient population ever studied in a U.S. Pivotal Trial

EVOLVE II Clinical Trial Study Overview: 

Patients with ≤3 native coronary artery lesions in ≤2 major epicardial vessels; lesion length ≤34 mm, RVD ≥2.25 mm ≤4.0, %DS> 50 <100 (excluded LM disease, SVG, CTO, or recent STEMI)

EVOLVE II Clinical Trial Baseline Characteristics for the SYNERGY Stent Arm

EVOLVE II Clinical Trial - Presented by Dean Kereiakes, MD at AHA 2014.

Zero Definite Stent Thrombosis (ST) Events in SYNERGY Stent Arm after 24 Hours

12 Month ST Rates

EVOLVE II Clinical Trial - Presented by Dean Kereiakes, MD at AHA 2014.
* ST Event occurred on day 6

Outstanding Clinical Outcomes in a Complex Patient Population

Primary Endpoint of Target Lesion Failure1 (TLF) Met in both Intent to Treat and in Per Protocol Patient Populations

Top